Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;209(2):315-322.
doi: 10.1007/s10549-024-07494-5. Epub 2024 Sep 15.

Differential prognostic value of residual nodal burden in breast cancer subtypes

Christine Hong Ngoc Che Thai  1 , Selena J An  1 , Conner R Haase  1 , Julia M Selfridge  1   2 , Chris B Agala  1   3 , Philip M Spanheimer  4   5   6
Affiliations

Differential prognostic value of residual nodal burden in breast cancer subtypes

Christine Hong Ngoc Che Thai et al. Breast Cancer Res Treat. 2025 Jan.

Abstract

Purpose: Residual cancer burden (RCB) index after neoadjuvant chemotherapy (NAC) is highly prognostic in patients with breast cancer (BC) but does not account for subtype or the precise impact of residual nodal burden (RNB). We aimed to precisely define the effect of RNB on survival by subtypes.

Methods: Adult women with non-metastatic BC diagnosed from 2006 to 2021 in the National Cancer Database (NCDB) who received NAC followed by surgery within 8 months were included. RNB was also evaluated as a predictor of mortality with multivariable logistic regression. Kaplan-Meier analyses were performed to compare overall survival.

Results: 51,917 patients were included. After adjustment, ypN stage was the strongest predictor of mortality, with an odds ratio (OR) of 2.24 (95% CI 2.08-2.41) for ypN1 vs ypN0 and increased with increasing nodal burden-ypN2 vs ypN0 OR 5.03, 95% CI 4.60-5.51 and ypN3 vs ypN0 OR 8.85, 95% CI 7.88-9.93. Stratification of survival curves with higher RNB is most pronounced for triple-negative breast cancer (TNBC) with an absolute difference of 64% in 5-year overall survival between ypN0 and ypN3 patients, and lowest for the ER+/HER2- subtype with a 25% absolute difference in 5-year OS between ypN0 and ypN3 patients. On interaction analysis, ypN status was a stronger predictor of mortality for the TNBC subtype compared to other subtypes.

Conclusion: RNB has a significantly different impact on survival by BC subtypes. Future study of optimal therapeutic strategies for patients with residual nodal disease after NAC should account for subtype-specific differences in prognosis.

Keywords: Breast cancer subtypes; Neoadjuvant chemotherapy; ypN status.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no competing interests.

Figures

Fig 1.
Fig 1.
Kaplan-Meier analysis of overall survival among patients with clinically node-positive breast cancer receiving neoadjuvant chemotherapy, by subtype and ypN
Fig 2.
Fig 2.
Forest Plot demonstrating the odds ratio for mortality of increasing nodal stage within each receptor subtype.
See this image and copyright information in PMC

Update of

References

    1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS et al. (2000) Molecular portraits of human breast tumours. Nature, 406(6797), 747–752. 10.1038/35021093 - DOI - PubMed
    1. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America, 98(19), 10869–10874. 10.1073/pnas.191367098 - DOI - PMC - PubMed
    1. Spanheimer PM, Carr JC, Thomas A, Sugg SL, Scott-Conner CE, Liao J, & Weigel RJ (2013) The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer. American journal of surgery, 206(1), 2–7. 10.1016/j.amjsurg.2012.10.025 - DOI - PMC - PubMed
    1. Choi M, Park YH, Ahn JS, Im YH, Nam SJ, Cho SY, & Cho EY (2017) Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period. Journal of pathology and translational medicine, 51(1), 69–78. 10.4132/jptm.2016.10.05 - DOI - PMC - PubMed
    1. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H et al. (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25(28), 4414–4422. 10.1200/JCO.2007.10.6823 - DOI - PubMed

Substances